Veracyte, Inc. Reports Financial Results for the Third Quarter 2026

Veracyte reported third-quarter 2026 financial results, with CEO Marc Stapley citing performance driven by profitability and cash generation. Afirma test performance exceeded expectations, while Decipher Prostate volume was below internal projections. Management said it remains confident in the company’s long-term outlook; the article provided no specific financial figures or stock-price impact.